Abbott Laboratories on Pace for Largest Percent Decrease Since October 2023 — Data Talk
Abbott Laboratories (ABT) is currently at $105.74, down $3.46 or 3.17%
--Would be lowest close since Dec. 8, 2023, when it closed at $104.51
--On pace for largest percent decrease since Oct. 11, 2023, when it fell 5.04%
--Currently down three of the past four days
--Down 6.96% month-to-date
--Down 3.93% year-to-date
--Down 25.25% from its all-time closing high of $141.46 on Dec. 27, 2021
--Down 5.83% from 52 weeks ago (April 19, 2023), when it closed at $112.29
--Down 12.58% from its 52-week closing high of $120.96 on March 8, 2024
--Up 17.25% from its 52-week closing low of $90.19 on Oct. 12, 2023
--Traded as low as $104.25; lowest intraday level since Dec. 11, 2023, when it hit $104.21
--Down 4.54% at today's intraday low; largest intraday percent decrease since March 15, 2024, when it fell as much as 5.54%
All data as of 10:38:45 AM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
April 17, 2024 10:55 ET (14:55 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track